SEHK:3692Pharmaceuticals
Hansoh Pharmaceutical Group SEHK 3692 Valuation After New Breakthrough Therapy And Hypertension Trial Approvals
Regulatory milestones put Hansoh Pharmaceutical Group (SEHK:3692) pipeline in focus
Hansoh Pharmaceutical Group (SEHK:3692) has reported two fresh milestones from China’s National Medical Products Administration, including Breakthrough-Therapy-Designated Drug status for its oncology candidate HS-20093 and new clinical trial approvals for hypertension therapy HS-10522.
See our latest analysis for Hansoh Pharmaceutical Group.
Despite the regulatory momentum, Hansoh Pharmaceutical Group’s share...